November 18, 2026
Frederick, Maryland — Ayatris Inc., a biotechnology company developing advanced organoid and organ-on-chip platforms, today announced it has been awarded $1 million through TEDCO's Equitech Growth Fund (EGF) Advanced Laboratory program to establish infrastructure supporting human-relevant drug discovery and translational research in Maryland.
The award supports Ayatris' Organoid and Organ-on-Chip Infrastructure Initiative, an effort to establish advanced laboratory capabilities for predictive drug discovery and translational research. The initiative will integrate microfluidic chip manufacturing, human sample biobanking, vascularized organoid technologies, advanced imaging, molecular characterization, and automation-enabled workflows. The infrastructure will be located at the Frederick Innovation Technology Center (FITCI), enabling rapid deployment and collaboration across Maryland's life sciences ecosystem.
“This award represents a significant milestone for Ayatris and validates our vision of building next-generation platforms that better predict human biology and accelerate therapeutic innovation. As the industry continues to embrace more predictive, human-centered approaches to research and development, Maryland has a unique opportunity to lead. We are grateful to TEDCO for its support and to our partners across the region who share our commitment to scientific innovation, economic growth, and improving healthcare outcomes.”
Growing adoption of organoid and organ-on-chip technologies is transforming how researchers study human biology and develop new therapies. These platforms are emerging as powerful tools for studying disease mechanisms, evaluating drug safety and efficacy, and advancing more predictive approaches to therapeutic development.
Supported by the TEDCO Equitech Growth Fund, Ayatris is building an integrated research infrastructure that combines organoid science, organ-on-chip technologies, advanced imaging, and translational research capabilities within a collaborative environment. The initiative is intended to expand access to advanced research tools and foster partnerships among academic institutions, healthcare organizations, government laboratories, and industry stakeholders.
Ayatris' technology portfolio includes organoid and organ-on-chip platforms designed to create sophisticated, multi-organ models of human biology for applications in drug discovery, disease modeling, and translational research. By combining these technologies with scalable infrastructure and strategic partnerships, the company aims to accelerate the development and evaluation of safer, more effective therapies.
About Ayatris Inc.
Ayatris Inc. is a Maryland-based biotechnology company developing advanced organoid and organ-on-chip technologies for drug discovery, disease modeling, and precision medicine. Through its proprietary and licensed technologies, Ayatris is building scalable, physiologically relevant platforms that help researchers and industry partners accelerate therapeutic development while enabling more human-relevant approaches to biomedical research. The company is headquartered in Frederick, Maryland.
About TEDCO and the Equitech Growth Fund
TEDCO (Maryland Technology Development Corporation) supports Maryland's innovation economy by investing in technology and life science companies, entrepreneurs, and strategic initiatives across the state. The Equitech Growth Fund (EGF) was established to advance inclusive economic growth by supporting projects that expand opportunity, strengthen innovation infrastructure, and create long-term economic impact throughout Maryland.
Learn more about the 2026 Equitech Growth Fund awardees in TEDCO's announcement: TEDCO Announces Awarding $4.3 Million Across Nine Equitech Growth Fund Awardees.
Media Contact
Srujana Cherukuri, Founder
Ayatris Inc.
[email protected]